Sanjay Chavda, MD
Pulmonary Disease · Hopkinsville, KYNPI 1437124484
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,668 of the $9,499 with a category attached, or 80.7%. It is spread thinly across 44 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 454 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Jazz Pharmaceuticals Inc.$1K
- Boehringer Ingelheim$767
- Actelion Pharmaceuticals US, Inc.$748
- Amgen$440
- plus $3K from 38 others
Across 4 payments — averaging $1014.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$4K
What the payments were for
- Consulting fees$1,50016%
- Speaking & faculty fees$1001%
- Food & beverage$7,66881%
- Education$2322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,499 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 16 | $405,244 |
| OfevNintedanib Esylate | 18 | $230,676 |
| OpsumitMacitentan | 13 | $163,600 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 167 | $151,000 |
| Dupixent PenDupilumab | 26 | $106,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $77,191 |
| Fasenra PenBenralizumab | 13 | $73,950 |
| OzempicSemaglutide | 56 | $57,986 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $54,248 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $46,564 |
| EliquisApixaban | 95 | $38,788 |
| MounjaroTirzepatide | 24 | $27,028 |
| JardianceEmpagliflozin | 49 | $25,041 |
| Spiriva RespimatTiotropium Bromide | 22 | $18,996 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $15,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $748 | $568,84529 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Jardiance, Spiriva Respimat | $767 | $321,276163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,371 | $220,733279 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $1,612 | $90,593113 claims |
| Novo NordiskOzempic | $128 | $57,98656 claims |
| PfizerEliquis | $25 | $38,78895 claims |
| Lilly USA, LLCMounjaro | $238 | $27,02824 claims |
| Johnson & JohnsonXarelto | $153 | $14,70936 claims |
| MerckBelsomra | $172 | $6,75316 claims |
| AbbVieLinzess | $51 | $6,65011 claims |
| NovartisEntresto | $76 | $6,10317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Hopkinsville
- Manoj MajmudarHopkinsville$17K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.